-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head-To-Head Analysis: Lisata Therapeutics (NASDAQ:LSTA) Vs. Ontrak (NASDAQ:OTRK)
Head-To-Head Analysis: Lisata Therapeutics (NASDAQ:LSTA) Vs. Ontrak (NASDAQ:OTRK)
Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and Ontrak (NASDAQ:OTRK – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Institutional & Insider Ownership
6.0% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of Ontrak shares are owned by institutional investors. 2.2% of Lisata Therapeutics shares are owned by insiders. Comparatively, 46.6% of Ontrak shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Get Lisata Therapeutics alerts:Volatility & Risk
Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.
Earnings and Valuation
This table compares Lisata Therapeutics and Ontrak's top-line revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.30 |
| Ontrak | $84.13 million | 0.30 | -$37.14 million | ($3.38) | -0.28 |
Lisata Therapeutics has higher earnings, but lower revenue than Ontrak. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ontrak, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Lisata Therapeutics and Ontrak, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Ontrak | 0 | 0 | 0 | 0 | N/A |
Lisata Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 313.79%. Ontrak has a consensus target price of $2.27, suggesting a potential upside of 141.78%. Given Lisata Therapeutics' higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Ontrak.
Profitability
This table compares Lisata Therapeutics and Ontrak's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
| Ontrak | -279.90% | -183.58% | -92.71% |
About Lisata Therapeutics
(Get Rating)
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
About Ontrak
(Get Rating)
Ontrak, Inc. engages in the provision of data analytics based behavioral health management and integrated treatment services to health plans. It offers services through its Ontrak platform solution, which is designed to improve member health, and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and Ontrak (NASDAQ:OTRK – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Lisata Therapeutics（纳斯达克股票代码：LSTA — Get Rating）和Ontrak（纳斯达克股票代码：OTRK — Get Rating）都是小型医疗公司，但哪种投资更好？我们将根据分析师建议的强度、估值、收益、盈利能力、机构所有权、风险和股息对这两家企业进行比较。
Institutional & Insider Ownership
机构所有权和内部所有权
6.0% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 49.8% of Ontrak shares are owned by institutional investors. 2.2% of Lisata Therapeutics shares are owned by insiders. Comparatively, 46.6% of Ontrak shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Lisata Therapeutics6.0％的股份由机构投资者持有。相比之下，49.8％的Ontrak股票由机构投资者持有。2.2％的Lisata Therapeutics股票由内部人士持有。相比之下，有46.6％的Ontrak股份由内部人士持有。强大的机构所有权表明，捐赠基金、对冲基金和大型基金经理认为一家公司已为长期增长做好了准备。
Volatility & Risk
波动性与风险
Lisata Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500.
Lisata Therapeutics的beta值为1.04，这表明其股价的波动性比标准普尔500指数高4％。相比之下，Ontrak的beta值为2.16，这表明其股价的波动性比标准普尔500指数高116％。
Earnings and Valuation
收益和估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lisata Therapeutics | N/A | N/A | -$27.47 million | ($12.23) | -0.30 |
| Ontrak | $84.13 million | 0.30 | -$37.14 million | ($3.38) | -0.28 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 丽莎塔疗法 | 不适用 | 不适用 | -2747 万美元 | (12.23 美元) | -0.30 |
| Ontrak | 8413 万美元 | 0.30 | -3,714 万美元 | (3.38 美元) | -0.28 |
Lisata Therapeutics has higher earnings, but lower revenue than Ontrak. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Ontrak, indicating that it is currently the more affordable of the two stocks.
与Ontrak相比，Lisata Therapeutics的收益更高，但收入更低。Lisata Therapeutics的市盈率低于Ontrak，这表明它目前是这两只股票中更实惠的一只。
Analyst Recommendations
分析师建议
This is a summary of recent recommendations and price targets for Lisata Therapeutics and Ontrak, as provided by MarketBeat.com.
这是Marketbeat.com提供的Lisata Therapeutics和Ontrak的最新建议和目标价格的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lisata Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Ontrak | 0 | 0 | 0 | 0 | N/A |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 丽莎塔疗法 | 0 | 0 | 2 | 0 | 3.00 |
| Ontrak | 0 | 0 | 0 | 0 | 不适用 |
Lisata Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 313.79%. Ontrak has a consensus target price of $2.27, suggesting a potential upside of 141.78%. Given Lisata Therapeutics' higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Ontrak.
Lisata Therapeutics目前的共识目标价为15.00美元，这表明潜在的上涨空间为313.79％。Ontrak的共识目标价为2.27美元，这表明潜在的上涨空间为141.78％。鉴于Lisata Therapeutics可能更高的上行空间，分析师显然认为Lisata Therapeutics比Ontrak更有利。
Profitability
盈利能力
This table compares Lisata Therapeutics and Ontrak's net margins, return on equity and return on assets.
该表比较了Lisata Therapeutics和Ontrak的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Lisata Therapeutics | N/A | -29.53% | -27.96% |
| Ontrak | -279.90% | -183.58% | -92.71% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 丽莎塔疗法 | 不适用 | -29.53% | -27.96% |
| Ontrak | -279.90% | -183.58% | -92.71% |
About Lisata Therapeutics
关于 Lisata Therapeu
(Get Rating)
（获取评分）
Lisata Therapeutics, Inc. develops biopharmaceuticals. It is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. It is designed to modify the tumor microenvironment by activating a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. The company is headquartered in Basking Ridge, NJ.
Lisata Therapeutics, Inc. 开发生物制药。它从事用于治疗晚期实体瘤和其他主要疾病的创新疗法的发现、开发和商业化。它旨在通过激活一种新的摄取途径来改变肿瘤微环境，使抗癌药物能够更有效地穿透实体瘤。该公司总部位于新泽西州巴斯金里奇。
About Ontrak
关于 Ontrak
(Get Rating)
（获取评分）
Ontrak, Inc. engages in the provision of data analytics based behavioral health management and integrated treatment services to health plans. It offers services through its Ontrak platform solution, which is designed to improve member health, and at the same time, lower costs to the insurer for underserved populations where behavioral health conditions cause or exacerbate co-existing medical conditions. The company was founded by Terren S. Peizer in February 2003 and is headquartered in Santa Monica, CA.
Ontrak, Inc. 致力于为健康计划提供基于数据分析的行为健康管理和综合治疗服务。它通过其Ontrak平台解决方案提供服务，该解决方案旨在改善成员的健康状况，同时为服务不足的人群降低保险公司的成本，这些人群的行为健康状况会导致或加剧共同存在的疾病。该公司由 Terren S. Peizer 于 2003 年 2 月创立，总部位于加利福尼亚州圣莫尼卡。
Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Lisata Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Lisata Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧